The $47.5 million Lang Walker Medical Research Building – Macarthur has received state significant development approval.
The project team is currently reviewing tenders and construction is expected to commence in the fourth quarter of this year. Completion is scheduled in 2024.
Western Sydney University’s facility will be delivered in partnership with South Western Sydney Local Health District, the Ingham Institute for Applied Medical Research and UNSW Sydney.
It will bring together within the Campbelltown Hospital precinct world leading researchers and clinicians across many disciplines.
Their main focus will be on the complex health challenges facing our fast-growing region, from mental illness to diabetes, paediatrics and addiction medicine.
A cutting edge concept design, the five storey medical research building will be a cornerstone of the multi-million dollar redevelopment of Campbelltown Hospital and the broader Campbelltown Health and Education precinct, and home to the Ingham Institute for Applied Medical Research Macarthur.
Award winning Australian architects BVN have designed the building with a commitment to achieving 5 Star certification from the Green Building Council of Australia.
Walker Corporation executive chairman Lang Walker said he was proud of his company’s donation of over $20 million to establish the new research facility.
“What an exciting milestone in our visionary collaboration with our research partners and Western Sydney University as we get the shovels ready to turn the first sod on this facility and ultimately deliver vital health solutions to families in South Western Sydney,” Mr Walker said.
Terry Goldacre, the chairman of Ingham Institute for Applied Medical Research said they were proud to be a partner.
“Ingham Institute – Macarthur will be another centre of excellence, adding to Ingham Institute – Liverpool, and growing our research and commercialisation capabilities,” Mr Goldacre said.
“We will continue to connect our clinicians and researchers with local and global industry to accelerate cutting edge health solutions supported by our world-class clinical trials capabilities.”
